for the treatment of subarachnoid hemorrhage. based rare and orphan diseases pharmaceutical company to improve its product portfolio by adding potential drug candidate GTX-104 manufactured by Grace Therapeutics, Inc. For instance, in August 2021, Acasti Pharma Inc., a Canada based late-stage specialty pharmaceutical company announced that it has completed the acquisition of Grace Therapeutics, Inc., a U.S.
patent for its drug Tenectase (tenecteplase), which can be used to treat brain clots in case of stroke.įurthermore, key players operating in the global brain hemorrhage market are focusing on adoption of inorganic growth strategies such as acquisitions, mergers, and collaborations, in order to expand their market presence in the global market. For instance, in July 2018, Gennova Biopharmaceuticals Limited, an India based pharmaceutical company received the U.S. Moreover, increasing approvals of novel products is expected to drive the market growth over the forecast period. Parliament in May 2019, it is estimated that the number of hospital admissions due to traumatic brain injury or acquired brain injury has increased from around 235,000 admissions in 2001 to 304,800 admissions in 2018, wherein head injury and stroke accounted for the maximum number of cases. These key trends are expected to aid in growth of the global brain hemorrhage market.įor instance, according to an article published by The House of Commons Library, a research and information service provider for the U.K.
Key trends in the market include increasing incidence of head injury, brain hemorrhage, and hypertension, increasing approval of novel products, and increasing collaborations and acquisitions among key players.
Key Trends and Analysis of the Global Brain Hemorrhage Market: 29, 2021 (GLOBE NEWSWIRE) - According to Coherent Market Insights, the global brain hemorrhage market is estimated to be valued at US$ 179.8 million in 2021 and is expected to exhibit a CAGR of 6.0% over the forecast period (2021-2028).
0 kommentar(er)
